I am currently working as Asscociate research scientist at Yale University. Previously I worked as Postdoctoral fellow at National Institutes of Health, USA. My current work is on infectious diseases such as malaria, tuberculosis, Lyme, Anthrax. In my project, I study immune correlates of protection to malaria. I have about 10 years of post-PhD experience in Global health, Immunology and Microbiology. I did my PhD from CSIR-Institute of Genomics and Integrative Biology, Delhi, India working on bacterial pathogens M. tuberculosis and other gram-positive bacterial pathogens. I worked as Vaccine Research Innovation awardee at Translational Health Science and Technology Institute in India.
I have 26 publications in International peer-reviewed journals and have published 4 Book chapters. My current h-index is 18. In the recent past, I have served as reviewer for Frontiers Journal, MDPI journals, Nature press journals, Medicine, Pathogen and vectors, BMC Microbiology, Archives of Microbiology, Journal of Antimicrobial Chemotherapy, and Indian Journal of Microbiology.
Dr. Lalit Batra is a Research Scientist within the Center for Predictive Medicine at the University of Louisville.
His research interests/output includes:
- Evaluation of efficacy Q-Griffithsin and AS1411 against SARS-CoV2 infection in hamsters, ferrets and hACE2 mice.
- Cancer Immunoprevention using a novel CD137 receptor agonist SA-4-1BBL molecule.
- Evaluated and published the role of novel SA-4-1BBL molecule as stand-alone monotherapeutics agent for Cancer Immunoprevention against TC-1, huMUC-1 and 3LL mouse tumor models.
- Evaluating the monotherapeutic role of SA-4-1BBL molecule against variety of tumor models such as melanoma, lymphoma, breast cancer and spontaneous cancer models.
- Vaccine approaches using SA-4-1BBL molecule against Yersinia pestis Infection (ABSL3).
- Evaluated and published the role of SA-4-1BBL as an adjuvant with the lead Y. pestis antigen (rF1-V) against lethal pneumonic plague challenge in BALB/c and C57BL/6 mice.
- Development of immunomodulatory protocols for overcoming allograft rejection for Type I Diabetes Mellitus (T1D).
- Evaluated and published the efficacy of immunomodulatory molecules such as SA-PDL1, SA-FasL and SA-CD47 for prevention of allograft rejection in chemically diabetic Mouse models.
- Evaluating the efficacy of SA-FasL for reversal of diabetes in recent-onset NOD mice.
Professor of Microbiology and Immunology at the School of Medicine University of North Carolina Chapel Hill. Our lab is working to understand the basic biology and pathogenesis of M. tuberculosis as a step toward developing new tuberculosis control and prevention strategies.
Dr. Mario Alberto Flores-Valdez is a Professor in the Medical and Pharmaceutical Biotechnology Unit, CIATEJ, A.C., Guadalajara, Jalisco, Mexico (2007-present). He is a member of the National System of Researchers (SNI), and a member of the Mexican Academy of Sciences. He was a Stanford University Medical Center postdoctoral fellow (2004-2007), where he received a Dean's Fellowship Award (2006) to conduct research on Tuberculosis. He worked in UNAM as Research Assistant for Prof. Jaime Mora (2004) and Prof. Emundo Calva (2003). He has received a Ph.D. in Biochemistry from UNAM (1999-2003), a M.Sc. in Molecular Biology and Genetic Engineering from UANL (1996-1999) and a B.Sc. from Universidad de Sonora (1991-1996) in Chemistry and Biology. He received fellowships from CONACYT for M.Sc. and Ph.D. studies and in M.Sc. and B.Sc. has received Diplomas as Best Student. He has expertise in Tuberculosis, particularly in developing recombinant BCG strains. He has been PI for 7 grants from 2008 to date, focused in studies about tuberculosis vaccine development and basic aspects of mycobacterial physiology.
Delia Goletti MD, PhD, Infectious Diseases specialist. In 1992 she joined the Laboratory of Immunoregulation at the National Institutes of Health (chief Dr Fauci) working on HIV pathogenesis. In 1999 she joined the National Institute for Infectious Diseases in Rome. She has clinical duties on the tuberculosis (TB) clinic and responsibility of the Translational Research Unit where she works on TB pathogenesis, TB immunodiagnostic tests and impact of Heminths infection on HIV and TB disease.
Max studied biochemistry and molecular biology in Argentina. In 2005, he was awarded a PhD in cell biology where he focused on the interactions between intracellular pathogens and the autophagic pathway. After that, he was in Gareth Griffiths Laboratory at EMBL, Heidelberg, Germany as a postdoctoral fellow of the von Humboldt foundation and EMBO focusing on the cell biology of macrophages and mycobacteria. In 2009, he became the head of the Junior Research Group “Phagosome Biology” at the Helmholtz Centre for Infection Research in Braunschweig, Germany. In 2012, he was recruited as a Programme Leader Track at the National Institute for Medical Research in London. Since 2015, he is a group leader at the Francis Crick Institute in London where he is developing imaging technologies and cellular models of infection to investigate the host-pathogen interactions in tuberculosis.
Senior Lecturer in Communicable Disease Epidemiology, School of Public Health, University of Sydney; Public Health Lead and Node Leader for Mass Gathering Medicine, Marie Bashir Institute, University of Sydney; Honorary Life Fellow, St Andrew's College within the University of Sydney; Senior Member and College Research Associate, Wolfson College, University of Cambridge
I studied medicine in Cambridge and during my junior doctor years was very interested in both neurology and infectious diseases. Clinically I specialised in medical microbiology, keeping a particular interest in neurological infections. For the past 3 years I have been in Saudi Arabia developing a pathogen genomics laboratory where I have gained first-hand experience of second generation sequencing and bioinformatics.
Infectious diseases and medical microbiology are undergoing the most significant shift since PCR was introduced. By the end of this decade, sequencing will have become the main option when investigating any outbreak or infection. I study the interface between genomics as a pure science and its translation into clinical and public health benefits.
At present I am examining the worldwide genomics of tuberculosis, the use of sequencing to characterise MRSA strains and the genomic variations in BCG vaccine strains used around the globe.
Dr. Sunhee Lee received her Ph.D. from the University of Arizona, where she worked in the laboratory of Dr. Christina Kennedy. Her graduate studies and research were focused on the area of plant-microbe interactions. After completing her graduate studies, Dr. Lee trained as a postdoctoral fellow in Dr. William Jacobs's laboratory at the Albert Einstein College of Medicine. In Dr. Jacob's laboratory, she researched the pathogenicity and immune responses of Mycobacterium tuberculosis and generated and tested live TB vaccine candidates that had been genetically engineered. Dr. Lee moved to Duke University as an Assistant Professor at the Human Vaccine Institute and Department of Molecular Genetics and Microbiology. As an investigator at Duke University, she continued to expand the research field to other host-mycobacterial interactions and their impact on immunogenicity and pathogenicity. Additionally, Dr. Lee's laboratory developed recombinant mycobacteria capable of eliciting strong HIV/SIV-specific immune responses. Currently, Dr. Lee is an Associate professor at the University of Texas Medical Branch, where she has been working to discover and develop new therapeutics and vaccines against M. tuberculosis and nontuberculous mycobacteria.
Dr McCreesh is an Assistant Professor in Infectious Disease Modelling at the London School of Hygiene and Tropical Medicine.
She is interested in understanding Mtb transmission patterns, and in how contact data can be used to develop a better understanding of potential M.tb. transmission sites, and to inform intervention strategies. She also works on the calibration and analysis of complex individual-based stochastic models, and is involved with a project to develop a history matching and model emulation R package.
Previous research includes HIV and schistosomiasis modelling, and work on respondent-driven sampling.
Doctor Sonia Oliveira holds a Licenciatura in Biology (pre-Bologna) and a Master in Cellular and Molecular Biology from the University of Aveiro, where she also specialized in medicinal plants, toxicology, murine models, and spermatogenesis. In 2011 she moved to Australia to work in Reproductive Biological Sciences. She later explored the nerve-cancer connection in Cancer, namely in female cancers, and completed her Ph.D. in Human Physiology ( with a significant component in Medical Biochemistry and Neurophysiology) from the University of Newcastle (Australia) in 2018. She then worked with biomimetic systems and nanotechnology in diabetes and stem cells. She explored multiple methods for primary and secondary cell culture, always with a keen interest in histopathology, cell biology, and rare disorders. Participated in >40 event(s). (Co-)Supervised MSc dissertation(s) and final projects for course completion of LSc/BSc. And works mostly in the area(s) of Natural sciences with emphasis on Molecular and Cellular Biology, and Medical and Health Sciences with emphasis on Neurosciences, Cancer, Reproduction, Toxicology, Biotechnology, and Stem cells. Also has collaborations in Microbiology, Biomaterials, and Communication and Information technologies.
Tanya Parish is the Senior VP of Drug Discovery at IDRI where she heads the TB Discovery Research group. Her work focuses on the discovery of new drugs that are effective at curing drug-sensitive and drug-resistant tuberculosis with the added goal of shortening the time it takes to cure disease. This encompasses a range of early stage drug discovery including drug target identification and validation, high throughput screening and medicinal chemistry. In addition, her group works to understand the pathogenic mechanisms and basic biology of the global pathogen Mycobacterium tuberculosis and using this information to inform drug discovery.
Tanya is a microbiologist by training, with a background in mycobacteriology. She received her PhD at the National Institute for Medical Research investigating gene regulation in mycobacteria followed by postdoctoral research at the London School of Hygiene & Tropical Medicine studying several facets of the biology of M. tuberculosis. Until recently, she held an academic post as Professor of Mycobacteriology at Barts and the London School of Medicine and Dentistry, and she is currently an Affiliate Professor in the Department of Global Health at the Univ. of Washington.
Tanya has edited several books on mycobacteria and published numerous papers on the basic biology and genetics of M. tuberculosis. She is Editor-in-Chief of Microbiology (UK), on the Editorial Board for PLOS One, PeerJ and Frontiers in Cell and Infection Microbiology.
Dr. Morteza Saki is a researcher within the Department of Microbiology at the Ahvaz Jundishapur University of Medical Sciences,Ahvaz, Iran.
His research focuses on the mechanisms of antimicrobial resistance in ESKAPE Pathogens, especially Klebsiella pneumoniae.